Resources are limited to the degree there is no push for more resources. We live in very very wealthy countries, and if we start “with resources limited” and stop there we don’t get the resources. It’s exactly the reason to push for more.
-
-
Replying to @zeynep @gregggonsalves and
If an idea is baseless or has already been shown to be pointless sure no need to waste more resources on it. But if that’s not yet the case, I don’t see the point of negotiating ourselves down without even asking for trials? Trillions are being spent on all this.
1 reply 0 retweets 16 likes -
Replying to @zeynep @gregggonsalves and
Totally agree - we need to keep fighting for the $$$ and investment in science infrastructure, especially for public health-focused studies and not just licensure studies. I only point out that if even $ were available, the staff for the trials are at the breaking point.
2 replies 0 retweets 14 likes -
Replying to @k_stephensonMD @zeynep and
We can run trials much more efficiently than we usually do. Particularly with a vaccine now being rolled out. We are talking about a trial of tens of thousands, to potentially improve access and early receipt for billions. We can do these trials if we wanted.
2 replies 1 retweet 13 likes -
Replying to @michaelmina_lab @zeynep and
Makes sense. So let’s get granular about the “we.” The NIH is pretty much at max capacity. So how about we turn abroad? That’s where pharma will likely go. And the ethics of placebo there? Seriously asking because the studies have to happen, we know this. But how?
3 replies 2 retweets 17 likes -
Replying to @k_stephensonMD @michaelmina_lab and
I think there are multiple countries where we could ethically run a prime vax+placebo/booster trial because it would be better than the current option for the people enrolled, which is no vaccine. We could also ask for volunteers here for booster delay, with monitoring.
1 reply 0 retweets 7 likes -
Replying to @zeynep @michaelmina_lab and
FWIW Johnson & Johnson is doing 2 separate efficacy trials right now - 2 doses and 1 dose. Should have read-out for the 1 dose in the next month. This is in no small part to advocacy from Dan Barouch and others 6 months ago. Good Q is why Pfizer and Moderna are not doing this.
2 replies 1 retweet 11 likes -
Replying to @k_stephensonMD @zeynep and
If they have data that says it's not worth our time, they should share it. Then OWS and others can make an educated decision about its value. If they don't have that data, then they should answer as to why it's not worth their $$ to test it. (See, I agree on the big issues!)
1 reply 1 retweet 7 likes -
Replying to @k_stephensonMD @zeynep and
Prasad Jallepalli, MD, PhD Retweeted Prasad Jallepalli, MD, PhD
As outlined below, Pfizer did report on neutralizing antibody titers after one versus two doses of the BioNTech vaccine. One dose gave a short term response, with titers peaking at day 14 and then dropping by day 28.https://twitter.com/jallepap/status/1343505565532758021 …
Prasad Jallepalli, MD, PhD added,
Prasad Jallepalli, MD, PhD @jallepapReplying to @jallepap @gregggonsalves and 4 othersHere's SARS-CoV2 specific data to ponder. Specifically, compare neutralizing antibody titers after one vs two doses of the BioNTech vaccine. Please keep in mind the graphs are on a log(10) scale https://www.cdc.gov/library/covid19/102720_covidupdate.html … pic.twitter.com/2JjI121rsZ3 replies 0 retweets 3 likes -
Well, yes, this is the confusing thing. Bc no-one expected those paltry dose 1 responses to be protective, and yet ... that little signal emerged. What I'm curious about is kinetics beyond a couple months. Or if they might know something about later boost responses.
2 replies 0 retweets 3 likes
Yeah. There have been a fair number of surprises along this path from trials.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.